Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

Author: Marshall John L.   Kindler Hedy   Deeken John   Bhargava Pankaj   Vogelzang Nicholas J.   Rizvi Naiyer   Luhtala Taina   Boylan Stacy   Dordal Margaret   Robertson Philmore   Hawkins Michael J.   Ratain Mark J.  

Publisher: Springer Publishing Company

ISSN: 0167-6997

Source: Investigational New Drugs, Vol.23, Iss.1, 2005-01, pp. : 31-37

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content